Yusimry (adalimumab-aqvh) — FDA-Approved Biosimilar to Humira (adalimumab)
TNF-alpha Inhibitor Biosimilar · Approved 2021 · $0–$35/mo for most insured patients
🔬 What Is Yusimry?
Yusimry (adalimumab-aqvh) is an FDA-approved biosimilar to Humira (adalimumab). A biosimilar is a biological medication that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Yusimry (adalimumab-aqvh) is a Humira biosimilar from Coherus BioSciences. It is approved for all Humira indications and may offer cost savings versus branded Humira. Coherus focuses exclusively on biosimilar development, supporting a strong quality commitment.
🛒 Order Yusimry — Direct from BiologicHealthPlus
Our pharmacist team will contact you within 2 hours to verify your prescription and insurance.
With Insurance
$0–$35/mo for most insured patients
Coherus Patient Support
Uninsured / PAP
Free
Income-based assistance
Yusimry Overview
| Property | Details |
|---|---|
| Brand Name | Yusimry |
| Generic Name | adalimumab-aqvh |
| Reference Biologic | Humira (adalimumab) |
| Manufacturer | Coherus BioSciences |
| Drug Class | TNF-alpha Inhibitor Biosimilar |
| FDA Approval | 2021 |
| Route | Subcutaneous injection |
| Approved Conditions | Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, HS, Uveitis, JIA |
| Copay Program | Coherus Patient Support — $0–$35/mo for most insured patients |
Approved Conditions
Yusimry vs Humira (adalimumab)
Yusimry has been demonstrated to be biosimilar to Humira (adalimumab) through comprehensive analytical, non-clinical, and clinical studies. The FDA requires that biosimilars have no clinically meaningful differences from the reference product. Patients who are stable on Humira (adalimumab) should discuss any potential switch to Yusimry with their prescriber.
| Factor | Yusimry | Humira (adalimumab) |
|---|---|---|
| FDA Status | Biosimilar (approved 2021) | Reference biologic |
| Active Ingredient | adalimumab-aqvh | adalimumab |
| Mechanism | TNF-alpha Inhibitor | Same |
| Approved Indications | Same as Humira (adalimumab) | Multiple FDA-approved |
| Typical Patient Cost | $0–$35/mo for most insured patients | $0–$35/mo (varies by plan) |
📚 Sources & Further Reading
Medical Disclaimer: Educational content reviewed by BiologicHealthPlus Clinical Team. Last reviewed: August 2026.